Le Lézard
Classified in: Health, Business
Subjects: ERN, CCA, FVT

Indivior First Half and Second Quarter 2020 Results Now Available; Conference Call With Leadership Today


SLOUGH, United Kingdom, and RICHMOND, Va., July 30, 2020 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that its first half and second quarter 2020 results press release is now available via the London Stock Exchange's Regulatory News Service (RNS) and on the "Investors" section of the company's website at www.indivior.com. 

Key members of Indivior's leadership team led by Mark Crossley, Chief Executive Officer, will host a conference call to discuss the results and address questions from qualified analysts and investors today (July 30th) at 12:00 p.m. London time (7:00 a.m. U.S. Eastern).

Access the Live Webcast / Call for the Results on July 30th
The live webcast event will be available on the "Investors" section of the company's website at www.indivior.com. The webcast link is https://edge.media-server.com/mmc/p/ot3s33ij. Participants also may access the results presentation telephonically: US participants 1-631-510-7495; international participants +44 (0) 2071 928000. Please reference confirmation number 6735858. A replay of the presentation will be available at www.indivior.com.

About Indivior 
Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease.

Building on its global portfolio of opioid dependence treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 800 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.

 

SOURCE Indivior PLC


These press releases may also interest you

at 17:53
DID YOU PURCHASE AND/OR INGEST U-DREAM IN CANADA ON OR AFTER AUGUST 18, 2014?
The following statement is being issued by Rice Harbut Elliott LLP regarding the Ruckman v. Biotrade Canada Ltd. et al. lawsuit: All persons in Canada who purchased or ingested U-Dream on or after August 18, 2014 (the "Class" or "Class Members")...

at 17:49
BioVaxys Technology Corp. Closes SECOND Tranche of Private Placement
BioVaxys Technology Corp. (FRA: 5LB) (the "Company") is pleased to announce that it has closed the second tranche (the "Second Tranche") of its previously announced non-brokered private placement (the "Private Placement") with the issuance of...

at 17:33
National Campaign Targets High Potassium Threat to Kidney Patients
The American Association of Kidney Patients (AAKP), the oldest and largest independent kidney patient consumer organization in the United States, announced the overwhelming success of its 2024 "Are You O-K+" campaign, which marked May 1 (5.1) as...

at 17:21
The Jackson Laboratory and AbTherx Announce Partnership to Enhance Therapeutic Antibody Discovery
The Jackson Laboratory (JAX), an independent, nonprofit biomedical research organization, and AbTherx, an innovator in biotechnology, announced a strategic partnership to develop and commercialize cutting-edge tools to expedite antibody discovery and...

at 17:00
Zepp Health Corporation Announces Receipt of NYSE Non-compliance Letter Regarding ADS Trading Price
Zepp Health Corporation ("Zepp" or the "Company") , a global leader in smart wearables and health technology, today announced that it has received a letter from the New York Stock Exchange (the "NYSE") dated April 30, 2024, notifying Zepp that it is...

at 16:55
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024
Revelation Biosciences, Inc. (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today reported its three months ended March...

More news about Health...


News published on and distributed by: